Virginia M. Pickel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Virginia M. Pickel has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Anjali M. Rajadhyaksha
Temple University
2 shared publications - Costantino Iadecola
Weill Cornell Medicine New York NY USA
2 shared publications - Francis S. Lee
Department of Psychiatry, Weill Cornell Medicine, New York, NY 10065, USA
2 shared publications Gang Wang
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, New York 10065
2 shared publicationsJune Chan
Feil Family Brain and Mind Research Institute and
2 shared publications- Michael J. Glass
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, United States
2 shared publications
Latest Publications
- Open Access
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadq4779
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia
Converging findings have established that the endocannabinoid (eCB) system serves as a possible target for the development of new treatments as a complement to opioid-based treatments. Here, we show in male and female mice that enhancing levels of the eCB, 2-arachidonoylglycerol (2-AG), through pharmacological inhibition of its catabolic enzyme, monoacylglycerol lipase (MAGL), either systemically or in the ventral tegmental area (VTA) with JZL184, leads to a substantial attenuation of the rewarding effects of opioids in mice using conditioned place preference and self-administration paradigms, without altering their analgesic properties. These effects are driven by cannabinoid receptor 1 (CB1R) within the VTA, as VTA CB1R conditional knockout counteracts JZL184’s effects. Using fiber photometry with fluorescent sensors for calcium and dopamine (DA), we find that enhancing 2-AG levels diminishes opioid reward–related nucleus accumbens (NAc) activity and DA neurotransmission. Together, these findings reveal that 2-AG diminishes the rewarding properties of opioids and provides a potential adjunctive therapeutic strategy for opioid-related analgesic treatments.
- 29 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (48) , eadq4779
Open AccessElevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia
Converging findings have established that the endocannabinoid (eCB) system serves as a possible target for the development of new treatments as a complement to opioid-based treatments. Here, we show in male and female mice that enhancing levels of the eCB, 2-arachidonoylglycerol (2-AG), through pharmacological inhibition of its catabolic enzyme, monoacylglycerol lipase (MAGL), either systemically or in the ventral tegmental area (VTA) with JZL184, leads to a substantial attenuation of the rewarding effects of opioids in mice using conditioned place preference and self-administration paradigms, without altering their analgesic properties. These effects are driven by cannabinoid receptor 1 (CB1R) within the VTA, as VTA CB1R conditional knockout counteracts JZL184’s effects. Using fiber photometry with fluorescent sensors for calcium and dopamine (DA), we find that enhancing 2-AG levels diminishes opioid reward–related nucleus accumbens (NAc) activity and DA neurotransmission. Together, these findings reveal that 2-AG diminishes the rewarding properties of opioids and provides a potential adjunctive therapeutic strategy for opioid-related analgesic treatments.
- Open Access
- 10 December 2020
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 41 (6) , 1349-1362
Tumor Necrosis Factor α Receptor Type 1 Activation in the Hypothalamic Paraventricular Nucleus Contributes to Glutamate Signaling and Angiotensin II-Dependent Hypertension
There are significant neurogenic and inflammatory influences on blood pressure, yet the role played by each of these processes in the development of hypertension is unclear. Tumor necrosis factor α (TNFα) has emerged as a critical modulator of blood pressure and neural plasticity; however, the mechanism by which TNFα signaling contributes to the development of hypertension is uncertain. We present evidence that following angiotensin II (AngII) infusion the TNFα type 1 receptor (TNFR1) plays a key role in heightened glutamate signaling in the hypothalamic paraventricular nucleus (PVN), a key central coordinator of blood pressure control. Fourteen day administration of a slow-pressor dose of AngII in male mice was associated with transcriptional and post-transcriptional (increased plasma membrane affiliation) regulation of TNFR1 in the PVN. Further, TNFR1 was shown to be critical for elevated NMDA-mediated excitatory currents in sympathoexcitatory PVN neurons following AngII infusion. Finally, silencing PVN TNFR1 prevented the increase in systolic blood pressure induced by AngII. These findings indicate that TNFR1 modulates a cellular pathway involving an increase in NMDA-mediated currents in the PVN following AngII infusion, suggesting a mechanism whereby TNFR1 activation contributes to hypertension via heightened hypothalamic glutamate-dependent signaling.SIGNIFICANCE STATEMENTInflammation is critical for the emergence of hypertension, yet the mechanisms by which inflammatory mediators contribute to this dysfunction are not clearly defined. We show that tumor necrosis factor α receptor 1 (TNFR1) in the paraventricular hypothalamic nucleus (PVN), a critical neuroregulator of cardiovascular function, plays an important role in the development of hypertension in mice. In the PVN, TNFR1 expression and plasma membrane localization are upregulated during hypertension induced by angiotensin II (AngII). Further, TNFR1 activation was essential for NMDA signaling and the heightening NMDA currents during hypertension. Finally, TNFR1 silencing in the PVN inhibits elevated blood pressure induced by AngII. These results point to a critical role for hypothalamic TNFR1 signaling in hypertension.
- 10 December 2020
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 41 (6) , 1349-1362
Open AccessTumor Necrosis Factor α Receptor Type 1 Activation in the Hypothalamic Paraventricular Nucleus Contributes to Glutamate Signaling and Angiotensin II-Dependent Hypertension
There are significant neurogenic and inflammatory influences on blood pressure, yet the role played by each of these processes in the development of hypertension is unclear. Tumor necrosis factor α (TNFα) has emerged as a critical modulator of blood pressure and neural plasticity; however, the mechanism by which TNFα signaling contributes to the development of hypertension is uncertain. We present evidence that following angiotensin II (AngII) infusion the TNFα type 1 receptor (TNFR1) plays a key role in heightened glutamate signaling in the hypothalamic paraventricular nucleus (PVN), a key central coordinator of blood pressure control. Fourteen day administration of a slow-pressor dose of AngII in male mice was associated with transcriptional and post-transcriptional (increased plasma membrane affiliation) regulation of TNFR1 in the PVN. Further, TNFR1 was shown to be critical for elevated NMDA-mediated excitatory currents in sympathoexcitatory PVN neurons following AngII infusion. Finally, silencing PVN TNFR1 prevented the increase in systolic blood pressure induced by AngII. These findings indicate that TNFR1 modulates a cellular pathway involving an increase in NMDA-mediated currents in the PVN following AngII infusion, suggesting a mechanism whereby TNFR1 activation contributes to hypertension via heightened hypothalamic glutamate-dependent signaling.SIGNIFICANCE STATEMENTInflammation is critical for the emergence of hypertension, yet the mechanisms by which inflammatory mediators contribute to this dysfunction are not clearly defined. We show that tumor necrosis factor α receptor 1 (TNFR1) in the paraventricular hypothalamic nucleus (PVN), a critical neuroregulator of cardiovascular function, plays an important role in the development of hypertension in mice. In the PVN, TNFR1 expression and plasma membrane localization are upregulated during hypertension induced by angiotensin II (AngII). Further, TNFR1 activation was essential for NMDA signaling and the heightening NMDA currents during hypertension. Finally, TNFR1 silencing in the PVN inhibits elevated blood pressure induced by AngII. These results point to a critical role for hypothalamic TNFR1 signaling in hypertension.
- Open Access
- 14 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (7) , eaay1502
Endocannabinoid genetic variation enhances vulnerability to THC reward in adolescent female mice
Adolescence represents a developmental period with the highest risk for initiating cannabis use. Little is known about whether genetic variation in the endocannabinoid system alters mesolimbic reward circuitry to produce vulnerability to the rewarding properties of the exogenous cannabinoid Δ9-tetrahydrocannabinol (THC). Using a genetic knock-in mouse model (FAAHC/A) that biologically recapitulates the human polymorphism associated with problematic drug use, we find that in adolescent female mice, but not male mice, this FAAH polymorphism enhances the mesolimbic dopamine circuitry projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and alters cannabinoid receptor 1 (CB1R) levels at inhibitory and excitatory terminals in the VTA. These developmental changes collectively increase vulnerability of adolescent female FAAHC/A mice to THC preference that persists into adulthood. Together, these findings suggest that this endocannabinoid genetic variant is a contributing factor for increased susceptibility to cannabis dependence in adolescent females.
- 14 February 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (7) , eaay1502
Open AccessEndocannabinoid genetic variation enhances vulnerability to THC reward in adolescent female mice
Adolescence represents a developmental period with the highest risk for initiating cannabis use. Little is known about whether genetic variation in the endocannabinoid system alters mesolimbic reward circuitry to produce vulnerability to the rewarding properties of the exogenous cannabinoid Δ9-tetrahydrocannabinol (THC). Using a genetic knock-in mouse model (FAAHC/A) that biologically recapitulates the human polymorphism associated with problematic drug use, we find that in adolescent female mice, but not male mice, this FAAH polymorphism enhances the mesolimbic dopamine circuitry projecting from the ventral tegmental area (VTA) to the nucleus accumbens (NAc) and alters cannabinoid receptor 1 (CB1R) levels at inhibitory and excitatory terminals in the VTA. These developmental changes collectively increase vulnerability of adolescent female FAAHC/A mice to THC preference that persists into adulthood. Together, these findings suggest that this endocannabinoid genetic variant is a contributing factor for increased susceptibility to cannabis dependence in adolescent females.
- Open Access
- 1 July 2015
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 35 (26) , 9558-9567
NMDA Receptor Plasticity in the Hypothalamic Paraventricular Nucleus Contributes to the Elevated Blood Pressure Produced by Angiotensin II
Hypertension induced by angiotensin II (Ang II) is associated with glutamate-dependent dysregulation of the hypothalamic paraventricular nucleus (PVN). Many forms of glutamate-dependent plasticity are mediated by NMDA receptor GluN1 subunit expression and the distribution of functional receptor to the plasma membrane of dendrites. Here, we use a combined ultrastructural and functional analysis to examine the relationship between PVN NMDA receptors and the blood pressure increase induced by chronic infusion of a low dose of Ang II. We report that the increase in blood pressure produced by a 2 week administration of a subpressor dose of Ang II results in an elevation in plasma membrane GluN1 in dendrites of PVN neurons in adult male mice. The functional implications of these observations are further demonstrated by the finding that GluN1 deletion in PVN neurons attenuated the Ang II-induced increases in blood pressure. These results indicate that NMDA receptor plasticity in PVN neurons significantly contributes to the elevated blood pressure mediated by Ang II.
- 1 July 2015
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 35 (26) , 9558-9567
Open AccessNMDA Receptor Plasticity in the Hypothalamic Paraventricular Nucleus Contributes to the Elevated Blood Pressure Produced by Angiotensin II
Hypertension induced by angiotensin II (Ang II) is associated with glutamate-dependent dysregulation of the hypothalamic paraventricular nucleus (PVN). Many forms of glutamate-dependent plasticity are mediated by NMDA receptor GluN1 subunit expression and the distribution of functional receptor to the plasma membrane of dendrites. Here, we use a combined ultrastructural and functional analysis to examine the relationship between PVN NMDA receptors and the blood pressure increase induced by chronic infusion of a low dose of Ang II. We report that the increase in blood pressure produced by a 2 week administration of a subpressor dose of Ang II results in an elevation in plasma membrane GluN1 in dendrites of PVN neurons in adult male mice. The functional implications of these observations are further demonstrated by the finding that GluN1 deletion in PVN neurons attenuated the Ang II-induced increases in blood pressure. These results indicate that NMDA receptor plasticity in PVN neurons significantly contributes to the elevated blood pressure mediated by Ang II.
- Open Access
- 16 March 2013
- Published by Wiley in Journal of Comparative Neurology
- Vol. 521 (13) , 2927-2946
Somatodendritic targeting of M5 muscarinic receptor in the rat ventral tegmental area: Implications for mesolimbic dopamine transmission
Muscarinic modulation of mesolimbic dopaminergic neurons in the ventral tegmental area (VTA) plays an important role in reward, potentially mediated through the M5 muscarinic acetylcholine receptor (M5R). However, the key sites for M5R‐mediated control of dopamine neurons within this region are still unknown. To address this question we examined the electron microscopic immunocytochemical localization of antipeptide antisera against M5R and the plasmalemmal dopamine transporter (DAT) in single sections through the rat VTA. M5R was located mainly to VTA somatodendritic profiles (71%;n= 627), at least one‐third (33.2%;n= 208) of which also contained DAT. The M5R immunoreactivity was distributed along cytoplasmic tubulovesicular endomembrane systems in somata and large dendrites, but was more often located at plasmalemmal sites in small dendrites, the majority of which did not express DAT. The M5R‐immunoreactive dendrites received a balanced input from unlabeled terminals forming either asymmetric or symmetric synapses. Compared with dendrites, M5R was less often seen in axon terminals, comprising only 10.8% (n= 102) of the total M5R‐labeled profiles. These terminals were usually presynaptic to unlabeled dendrites, suggesting that M5R activation can indirectly modulate non–DAT‐containing dendrites through presynaptic mechanisms. Our results provide the first ultrastructural evidence that in the VTA, M5R has a subcellular location conducive to major involvement in postsynaptic signaling in many dendrites, only some of which express DAT. These findings suggest that cognitive and rewarding effects ascribed to muscarinic activation in the VTA can primarily be credited to M5R activation at postsynaptic plasma membranes distinct from dopamine transport. J. Comp. Neurol. 521: 2927–2946, 2013.
- 16 March 2013
- Published by Wiley in Journal of Comparative Neurology
- Vol. 521 (13) , 2927-2946
Open AccessSomatodendritic targeting of M5 muscarinic receptor in the rat ventral tegmental area: Implications for mesolimbic dopamine transmission
Muscarinic modulation of mesolimbic dopaminergic neurons in the ventral tegmental area (VTA) plays an important role in reward, potentially mediated through the M5 muscarinic acetylcholine receptor (M5R). However, the key sites for M5R‐mediated control of dopamine neurons within this region are still unknown. To address this question we examined the electron microscopic immunocytochemical localization of antipeptide antisera against M5R and the plasmalemmal dopamine transporter (DAT) in single sections through the rat VTA. M5R was located mainly to VTA somatodendritic profiles (71%;n= 627), at least one‐third (33.2%;n= 208) of which also contained DAT. The M5R immunoreactivity was distributed along cytoplasmic tubulovesicular endomembrane systems in somata and large dendrites, but was more often located at plasmalemmal sites in small dendrites, the majority of which did not express DAT. The M5R‐immunoreactive dendrites received a balanced input from unlabeled terminals forming either asymmetric or symmetric synapses. Compared with dendrites, M5R was less often seen in axon terminals, comprising only 10.8% (n= 102) of the total M5R‐labeled profiles. These terminals were usually presynaptic to unlabeled dendrites, suggesting that M5R activation can indirectly modulate non–DAT‐containing dendrites through presynaptic mechanisms. Our results provide the first ultrastructural evidence that in the VTA, M5R has a subcellular location conducive to major involvement in postsynaptic signaling in many dendrites, only some of which express DAT. These findings suggest that cognitive and rewarding effects ascribed to muscarinic activation in the VTA can primarily be credited to M5R activation at postsynaptic plasma membranes distinct from dopamine transport. J. Comp. Neurol. 521: 2927–2946, 2013.
- Open Access
- 1 April 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (S1) , 993.4
Chronic intermittent hypoxia (CIH) disrupts neurovascular coupling and endothelium dependent responses in the mouse cerebral microcirculation
Sleep apnea, which leads to CIH, increases the incidence of stroke, but the mechanism is unknown (AJP 293:R1671, 2007). Brain function depends on a well regulated cerebral blood flow (CBF). The CBF increases induced by neural activity and endothelium‐dependent vasodilation are key factors in CBF regulation, and their dysfunction increases the brain's susceptibility to injury. We hypothesize that CIH exerts its deleterious effects on the brain by altering CBF regulation. Cerebrovascular regulation was examined in mice (n=5/group) subjected to CIH or sham (Sh) treatment for 35 days. Under chloralose‐urethane anesthesia, somatosensory cortex CBF was monitored by a laser‐Doppler probe through a cranial window. CIH elevated mean arterial pressure from 73±2 to 83±3 mmHg (p<0.05) and attenuated (p0.05), attesting to preservation of smooth muscle function. We conclude that CIH selectively impairs key homeostatic responses of the cerebral circulation, raising the possibility that CIH‐induced CBF dysfunction promotes cerebrovascular insufficiency and ischemic injury in sleep apnea patients (Supported by HL18974).
- 1 April 2009
- Published by Wiley in The FASEB Journal
- Vol. 23 (S1) , 993.4
Open AccessChronic intermittent hypoxia (CIH) disrupts neurovascular coupling and endothelium dependent responses in the mouse cerebral microcirculation
Sleep apnea, which leads to CIH, increases the incidence of stroke, but the mechanism is unknown (AJP 293:R1671, 2007). Brain function depends on a well regulated cerebral blood flow (CBF). The CBF increases induced by neural activity and endothelium‐dependent vasodilation are key factors in CBF regulation, and their dysfunction increases the brain's susceptibility to injury. We hypothesize that CIH exerts its deleterious effects on the brain by altering CBF regulation. Cerebrovascular regulation was examined in mice (n=5/group) subjected to CIH or sham (Sh) treatment for 35 days. Under chloralose‐urethane anesthesia, somatosensory cortex CBF was monitored by a laser‐Doppler probe through a cranial window. CIH elevated mean arterial pressure from 73±2 to 83±3 mmHg (p<0.05) and attenuated (p0.05), attesting to preservation of smooth muscle function. We conclude that CIH selectively impairs key homeostatic responses of the cerebral circulation, raising the possibility that CIH‐induced CBF dysfunction promotes cerebrovascular insufficiency and ischemic injury in sleep apnea patients (Supported by HL18974).
Presence of NMDA-type glutamate receptors in cingulate corticostriatal terminals and their postsynaptic targets
The glutamatergic projection from the anterior cingulate cortex to the medial caudate‐putamen nucleus (CPN) has been implicated in motor and cognitive functions, many of which are potently modulated by activation of N‐methyl‐D‐aspartate subtype of glutamate receptors (NMDARs). To determine the functional sites for NMDAR activation within this circuitry, we combined anterograde transport of biotinylated dextran amine (BDA) from deep layers of the rat anterior cingulate cortex with immunogold labeling of NMDAR subunit, NMDAR1, in the dorsomedial CPN. BDA‐containing axons were seen in patch‐like clusters in a neuropil that showed more uniform immunogold‐silver labeling for NMDAR1. Electron microscopy of these regions showed that BDA‐labeling was present exclusively in axons and terminals, 23% (98 of 421) of which also contained NMDAR1‐immunoreactivity (IR). BDA‐labeled terminals often apposed NMDAR1‐immunoreactive neuronal and glial profiles. These terminals also formed asymmetric excitatory‐type synapses with dendritic spines. Of 155 anterogradely labeled axon terminals forming asymmetric synapses, 34% were with NMDAR1‐labeled, and 66% with unlabeled dendritic spines. These results provide ultrastructural evidence for the involvement of NMDARs in presynaptic regulation of glutamate transmission, and in postsynaptic modulation of the excitability of spiny neurons in patch‐like compartments of the dorsomedial CPN. These dual NMDAR‐mediated actions are likely to play a major role in the acquisition of new behaviors and reward‐related processes that have been associated with cortical input to the striatal patch compartments. Synapse 35:300–310, 2000.
Presence of NMDA-type glutamate receptors in cingulate corticostriatal terminals and their postsynaptic targets
The glutamatergic projection from the anterior cingulate cortex to the medial caudate‐putamen nucleus (CPN) has been implicated in motor and cognitive functions, many of which are potently modulated by activation of N‐methyl‐D‐aspartate subtype of glutamate receptors (NMDARs). To determine the functional sites for NMDAR activation within this circuitry, we combined anterograde transport of biotinylated dextran amine (BDA) from deep layers of the rat anterior cingulate cortex with immunogold labeling of NMDAR subunit, NMDAR1, in the dorsomedial CPN. BDA‐containing axons were seen in patch‐like clusters in a neuropil that showed more uniform immunogold‐silver labeling for NMDAR1. Electron microscopy of these regions showed that BDA‐labeling was present exclusively in axons and terminals, 23% (98 of 421) of which also contained NMDAR1‐immunoreactivity (IR). BDA‐labeled terminals often apposed NMDAR1‐immunoreactive neuronal and glial profiles. These terminals also formed asymmetric excitatory‐type synapses with dendritic spines. Of 155 anterogradely labeled axon terminals forming asymmetric synapses, 34% were with NMDAR1‐labeled, and 66% with unlabeled dendritic spines. These results provide ultrastructural evidence for the involvement of NMDARs in presynaptic regulation of glutamate transmission, and in postsynaptic modulation of the excitability of spiny neurons in patch‐like compartments of the dorsomedial CPN. These dual NMDAR‐mediated actions are likely to play a major role in the acquisition of new behaviors and reward‐related processes that have been associated with cortical input to the striatal patch compartments. Synapse 35:300–310, 2000.
- Open Access
- 1 June 1995
- Published by Elsevier in Neuroscience Letters
- Vol. 193 (2) , 89-92
Co-localization of angiotensin II and gamma-aminobutyric acid in axon terminals in the rat subfornical organ
- 1 June 1995
- Published by Elsevier in Neuroscience Letters
- Vol. 193 (2) , 89-92
Open AccessCo-localization of angiotensin II and gamma-aminobutyric acid in axon terminals in the rat subfornical organ